Suchergebnisse - "Fuchs, Ota"

PubPharm (51)

11

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

enthalten in: Cardiovascular & hematological disorders, drug targets | 2019

von Fuchs, O.

12

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

enthalten in: Cardiovascular & hematological disorders drug targets | 2019

von Fuchs, O.

13

Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)

enthalten in: Leukemia research | 2018

von Jonasova, A. | Neuwirtova, R. | Polackova, H. | +9

14

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

enthalten in: PloS one | 2018

von Kuželová, K. | Brodská, B. | Schetelig, J. | +9

15

Proteomic analysis of serum for identification of potential biomarkers predicting response of patients with refractory multiple myeloma to bortezomib‑based therapy

enthalten in: Polish archives of internal medicine | 2017

von Fuchs, O.

CommentOn: Pol Arch Intern Med. 2017 Jun 30;127(6):392-400. - PMID 28546528

16

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

enthalten in: European journal of haematology | 2015

von Jonasova, A. | Bokorova, R. | Polak, J. | +12

17

Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia

enthalten in: PloS one | 2015

von Kuželová, K. | Brodská, B. | Fuchs, O. | +3

18

High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

enthalten in: European journal of haematology | 2015

von Jonasova, A. | Bokorova, R. | Polak, J. | +12

19

CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

enthalten in: Journal of hematology & oncology | 2014

von Hájková, H. | Fritz, M. | Haškovec, C. | +11

20

CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

enthalten in: Journal of hematology & oncology | 2014

von Hájková, H. | Fritz, M. | Haškovec, C. | +11